ITI, Takeda Pharma ink agreement to develop compounds for schizophrenia
Discovered by ITI, PDE1 inhibitors are preclinical stage compounds which are orally delivered and have the potential to treat many psychiatric and neurological diseases. As per the terms
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.